The Company has a resource-efficient structure, operating through an extensive network of research, development and manufacturing
subcontractors to develop drug candidates through clinical Phase I/II/III. Clavis Pharma presently has 30 employees and more
than 200 external collaborators worldwide.
External collaborators include front line research institutes and universities such as National Institutes of Health (NIH) and National Cancer Institute (NCI) and The European Organisation for Research and Treatment of Cancer (EORTC).
